Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Neoplasms of the CNS

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 106 articles:
HTML format
Text format



Single Articles


    April 2019
  1. HE Q, Zhang L, Zhang B, Shi X, et al
    Diagnostic accuracy of (13)N-ammonia PET, (11)C-methionine PET and (18)F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma.
    BMC Cancer. 2019;19:332.
    PubMed     Text format     Abstract available


  2. KOPER-LENKIEWICZ OM, Kaminska J, Milewska A, Sawicki K, et al
    Serum and cerebrospinal fluid Neudesin concentration and Neudesin Quotient as potential circulating biomarkers of a primary brain tumor.
    BMC Cancer. 2019;19:319.
    PubMed     Text format     Abstract available


  3. COWMAN S, Fan YN, Pizer B, See V, et al
    Decrease of Nibrin expression in chronic hypoxia is associated with hypoxia-induced chemoresistance in some brain tumour cells.
    BMC Cancer. 2019;19:300.
    PubMed     Text format     Abstract available


  4. DJUZENOVA CS, Fiedler V, Memmel S, Katzer A, et al
    Differential effects of the Akt inhibitor MK-2206 on migration and radiation sensitivity of glioblastoma cells.
    BMC Cancer. 2019;19:299.
    PubMed     Text format     Abstract available


    March 2019
  5. HUA C, Zhao G, Li Y, Bie L, et al
    Correction to: Minichromosome Maintenance (MCM) family as potential diagnostic and prognostic tumor markers for human gliomas.
    BMC Cancer. 2019;19:260.
    PubMed     Text format     Abstract available


  6. SUN L, Jin X, Xie L, Xu G, et al
    Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2019;19:247.
    PubMed     Text format     Abstract available


  7. LESUEUR P, Lequesne J, Grellard JM, Dugue A, et al
    Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol.
    BMC Cancer. 2019;19:198.
    PubMed     Text format     Abstract available


    February 2019
  8. LAPRIE A, Ken S, Filleron T, Lubrano V, et al
    Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imaging.
    BMC Cancer. 2019;19:167.
    PubMed     Text format     Abstract available


  9. OSTROVSKAYA A, Hick C, Hutchinson DS, Stringer BW, et al
    Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas.
    BMC Cancer. 2019;19:157.
    PubMed     Text format     Abstract available


  10. LI WY, Zhao TT, Xu HM, Wang ZN, et al
    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:145.
    PubMed     Text format     Abstract available


  11. HEYNCKES S, Daka K, Franco P, Gaebelein A, et al
    Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme.
    BMC Cancer. 2019;19:117.
    PubMed     Text format     Abstract available


    January 2019
  12. DARLIX A, Hirtz C, Thezenas S, Maceski A, et al
    The prognostic value of the Tau protein serum level in metastatic breast cancer patients and its correlation with brain metastases.
    BMC Cancer. 2019;19:110.
    PubMed     Text format     Abstract available


  13. ZUO MR, Liang RF, Li M, Xiang YF, et al
    A comprehensive study of risk factors for post-operative pneumonia following resection of meningioma.
    BMC Cancer. 2019;19:100.
    PubMed     Text format     Abstract available


  14. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Correction to: inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2019;19:101.
    PubMed     Text format     Abstract available


  15. LI Z, Mbah NE, Overmeyer JH, Sarver JG, et al
    The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma.
    BMC Cancer. 2019;19:77.
    PubMed     Text format     Abstract available


  16. KIM R, Keam B, Kim S, Kim M, et al
    Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors.
    BMC Cancer. 2019;19:19.
    PubMed     Text format     Abstract available


    December 2018
  17. TAN WL, Ng QS, Lim C, Tan EH, et al
    Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1288.
    PubMed     Text format     Abstract available


  18. FRAZAO L, do Carmo Martins M, Nunes VM, Pimentel J, et al
    BRAF V600E mutation and 9p21: CDKN2A/B and MTAP co-deletions - Markers in the clinical stratification of pediatric gliomas.
    BMC Cancer. 2018;18:1259.
    PubMed     Text format     Abstract available


  19. MOHAMMAD AS, Adkins CE, Shah N, Aljammal R, et al
    Permeability changes and effect of chemotherapy in brain adjacent to tumor in an experimental model of metastatic brain tumor from breast cancer.
    BMC Cancer. 2018;18:1225.
    PubMed     Text format     Abstract available


  20. MONNIER A, Boniface R, Bouvet R, Etcheverry A, et al
    The expression of EMX2 lead to cell cycle arrest in glioblastoma cell line.
    BMC Cancer. 2018;18:1213.
    PubMed     Text format     Abstract available


  21. LI L, Huang Y, Gao Y, Shi T, et al
    EGF/EGFR upregulates and cooperates with Netrin-4 to protect glioblastoma cells from DNA damage-induced senescence.
    BMC Cancer. 2018;18:1215.
    PubMed     Text format     Abstract available


  22. TAN WL, Ng QS, Lim C, Tan EH, et al
    Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases.
    BMC Cancer. 2018;18:1198.
    PubMed     Text format     Abstract available


    November 2018
  23. HWANG K, Lee KS, Choe G, Cho BG, et al
    Secondary glioblastoma after treatment of intracranial germinoma - would radiation-only therapy still be safe? Case report.
    BMC Cancer. 2018;18:1119.
    PubMed     Text format     Abstract available


    October 2018
  24. TUNG B, Ma D, Wang S, Oyinlade O, et al
    Kruppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    BMC Cancer. 2018;18:1025.
    PubMed     Text format     Abstract available


  25. AIKO N, Shimokawa T, Miyazaki K, Misumi Y, et al
    Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
    BMC Cancer. 2018;18:1012.
    PubMed     Text format     Abstract available


  26. DA SILVA BB, Eulalio Filho WMN, Costa PVL, Silva RA, et al
    A rare case of primary breast angiosarcoma in a male: a case report.
    BMC Cancer. 2018;18:978.
    PubMed     Text format     Abstract available


  27. LORIGUET L, Morisse MC, Dremaux J, Collet L, et al
    Combining genomic analyses with tumour-derived slice cultures for the characterization of an EGFR-activating kinase mutation in a case of glioblastoma.
    BMC Cancer. 2018;18:964.
    PubMed     Text format     Abstract available


  28. FOLYOVICH A, Varga V, Varallyay G, Kozak L, et al
    A case report of isolated distal upper extremity weakness due to cerebral metastasis involving the hand knob area.
    BMC Cancer. 2018;18:947.
    PubMed     Text format     Abstract available


    September 2018
  29. STRAUBE C, Kessel KA, Schmidt-Graf F, Krieg SM, et al
    A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey.
    BMC Cancer. 2018;18:907.
    PubMed     Text format     Abstract available


  30. SONG X, Shu XH, Wu ML, Zheng X, et al
    Postoperative resveratrol administration improves prognosis of rat orthotopic glioblastomas.
    BMC Cancer. 2018;18:871.
    PubMed     Text format     Abstract available


  31. MIKKELSEN VE, Stensjoen AL, Granli US, Berntsen EM, et al
    Angiogenesis and radiological tumor growth in patients with glioblastoma.
    BMC Cancer. 2018;18:862.
    PubMed     Text format     Abstract available


    August 2018
  32. URUGA H, Moriguchi S, Takahashi Y, Ogawa K, et al
    Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    BMC Cancer. 2018;18:825.
    PubMed     Text format     Abstract available


    July 2018
  33. DU D, Yuan J, Ma W, Ning J, et al
    Clinical significance of FBXO17 gene expression in high-grade glioma.
    BMC Cancer. 2018;18:773.
    PubMed     Text format     Abstract available


  34. KIM T, Choi HY, Lee HS, Jung SH, et al
    Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).
    BMC Cancer. 2018;18:729.
    PubMed     Text format     Abstract available


  35. ZHONG C, Chen Y, Tao B, Peng L, et al
    LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway.
    BMC Cancer. 2018;18:722.
    PubMed     Text format     Abstract available


    June 2018
  36. VALKONEN M, Haapasalo H, Rilla K, Tyynela-Korhonen K, et al
    Elevated expression of hyaluronan synthase 2 associates with decreased survival in diffusely infiltrating astrocytomas.
    BMC Cancer. 2018;18:664.
    PubMed     Text format     Abstract available


  37. POUCHIEU C, Gruber A, Berteaud E, Menegon P, et al
    Increasing incidence of central nervous system (CNS) tumors (2000-2012): findings from a population based registry in Gironde (France).
    BMC Cancer. 2018;18:653.
    PubMed     Text format     Abstract available


    May 2018
  38. WANG Y, Guan G, Cheng W, Jiang Y, et al
    ARL2 overexpression inhibits glioma proliferation and tumorigenicity via down-regulating AXL.
    BMC Cancer. 2018;18:599.
    PubMed     Text format     Abstract available


  39. KARJALAINEN SL, Haapasalo HK, Aspatwar A, Barker H, et al
    Carbonic anhydrase related protein expression in astrocytomas and oligodendroglial tumors.
    BMC Cancer. 2018;18:584.
    PubMed     Text format     Abstract available


  40. MARTINI M, de Pascalis I, D'Alessandris QG, Fiorentino V, et al
    VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.
    BMC Cancer. 2018;18:553.
    PubMed     Text format     Abstract available


  41. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
    The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    BMC Cancer. 2018;18:552.
    PubMed     Text format     Abstract available


  42. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
    Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    BMC Cancer. 2018;18:549.
    PubMed     Text format     Abstract available


  43. PEYSER A, Bristow SL, Hershlag A
    Two successful pregnancies following fertility preservation in a patient with anaplastic astrocytoma: a case report.
    BMC Cancer. 2018;18:544.
    PubMed     Text format     Abstract available


  44. LEE C, Lee J, Choi SA, Kim SK, et al
    M1 macrophage recruitment correlates with worse outcome in SHH Medulloblastomas.
    BMC Cancer. 2018;18:535.
    PubMed     Text format     Abstract available


  45. SCHULZE M, Hutterer M, Sabo A, Hoja S, et al
    Chronophin regulates active vitamin B6 levels and transcriptomic features of glioblastoma cell lines cultured under non-adherent, serum-free conditions.
    BMC Cancer. 2018;18:524.
    PubMed     Text format     Abstract available


  46. HEGGE B, Sjottem E, Mikkola I
    Generation of a PAX6 knockout glioblastoma cell line with changes in cell cycle distribution and sensitivity to oxidative stress.
    BMC Cancer. 2018;18:496.
    PubMed     Text format     Abstract available


    April 2018
  47. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
    Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    BMC Cancer. 2018;18:490.
    PubMed     Text format     Abstract available


  48. JIN J, Gao Y, Zhang J, Wang L, et al
    Incidence, pattern and prognosis of brain metastases in patients with metastatic triple negative breast cancer.
    BMC Cancer. 2018;18:446.
    PubMed     Text format     Abstract available


  49. LAUBER C, Klink B, Seifert M
    Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups.
    BMC Cancer. 2018;18:399.
    PubMed     Text format     Abstract available


  50. CHIO CC, Chen KY, Chang CK, Chuang JY, et al
    Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells.
    BMC Cancer. 2018;18:379.
    PubMed     Text format     Abstract available


  51. BOTTCHER MA, Held-Feindt J, Synowitz M, Lucius R, et al
    Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation.
    BMC Cancer. 2018;18:376.
    PubMed     Text format     Abstract available


  52. FATAI AA, Gamieldien J
    A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer.
    BMC Cancer. 2018;18:377.
    PubMed     Text format     Abstract available


    March 2018
  53. HUA G, Yanjiao H, Qian L, Jichao W, et al
    Detection of circulating tumor cells in patients with pituitary tumors.
    BMC Cancer. 2018;18:336.
    PubMed     Text format     Abstract available


  54. AABERG-JESSEN C, Sorensen MD, Matos ALSA, Moreira JM, et al
    Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas.
    BMC Cancer. 2018;18:270.
    PubMed     Text format     Abstract available


  55. RANJAN S, Quezado M, Garren N, Boris L, et al
    Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.
    BMC Cancer. 2018;18:239.
    PubMed     Text format     Abstract available


    February 2018
  56. HAN Y, Yan LF, Wang XB, Sun YZ, et al
    Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    BMC Cancer. 2018;18:215.
    PubMed     Text format     Abstract available


  57. SCHIMMEL WCM, Verhaak E, Hanssens PEJ, Gehring K, et al
    A randomised trial to compare cognitive outcome after gamma knife radiosurgery versus whole brain radiation therapy in patients with multiple brain metastases: research protocol CAR-study B.
    BMC Cancer. 2018;18:218.
    PubMed     Text format     Abstract available


  58. JIAO XD, Ding C, Zang YS, Yu G, et al
    Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report.
    BMC Cancer. 2018;18:206.
    PubMed     Text format     Abstract available


  59. TOTON E, Romaniuk A, Konieczna N, Hofmann J, et al
    Impact of PKCepsilon downregulation on autophagy in glioblastoma cells.
    BMC Cancer. 2018;18:185.
    PubMed     Text format     Abstract available


  60. MARITAZ C, Lemare F, Laplanche A, Demirdjian S, et al
    High-dose thiotepa-related neurotoxicity and the role of tramadol in children.
    BMC Cancer. 2018;18:177.
    PubMed     Text format     Abstract available


  61. AHN MJ, Lee K, Lee KH, Kim JW, et al
    Combination of anti-PD-1 therapy and stereotactic radiosurgery for a gastric cancer patient with brain metastasis: a case report.
    BMC Cancer. 2018;18:173.
    PubMed     Text format     Abstract available


  62. MOREN L, Perryman R, Crook T, Langer JK, et al
    Metabolomic profiling identifies distinct phenotypes for ASS1 positive and negative GBM.
    BMC Cancer. 2018;18:167.
    PubMed     Text format     Abstract available


  63. VASAIKAR S, Tsipras G, Landazuri N, Costa H, et al
    Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
    BMC Cancer. 2018;18:154.
    PubMed     Text format     Abstract available


  64. LIU F, Huang J, Zhang L, Fan F, et al
    Screening for distress in patients with primary brain tumor using distress thermometer: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:124.
    PubMed     Text format     Abstract available


    January 2018
  65. EISEMANN T, Costa B, Strelau J, Mittelbronn M, et al
    An advanced glioma cell invasion assay based on organotypic brain slice cultures.
    BMC Cancer. 2018;18:103.
    PubMed     Text format     Abstract available


  66. CHOU SY, Yen SL, Huang CC, Huang EY, et al
    Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.
    BMC Cancer. 2018;18:105.
    PubMed     Text format     Abstract available


  67. RICCIARDI GRR, Russo A, Franchina T, Schifano S, et al
    Efficacy of T-DM1 for leptomeningeal and brain metastases in a HER2 positive metastatic breast cancer patient: new directions for systemic therapy - a case report and literature review.
    BMC Cancer. 2018;18:97.
    PubMed     Text format     Abstract available


  68. GOLDSMITH CS, Kim SM, Karunarathna N, Neuendorff N, et al
    Inhibition of p38 MAPK activity leads to cell type-specific effects on the molecular circadian clock and time-dependent reduction of glioma cell invasiveness.
    BMC Cancer. 2018;18:43.
    PubMed     Text format     Abstract available


  69. XIA L, Fang C, Chen G, Sun C, et al
    Relationship between the extent of resection and the survival of patients with low-grade gliomas: a systematic review and meta-analysis.
    BMC Cancer. 2018;18:48.
    PubMed     Text format     Abstract available


  70. STRAUBE C, Scherb H, Gempt J, Kirschke J, et al
    Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA 17 - ARO 2016/3 - DKTK ROG trial).
    BMC Cancer. 2018;18:15.
    PubMed     Text format     Abstract available


    December 2017
  71. CHANG CH, Liu WT, Hung HC, Gean CY, et al
    Synergistic inhibition of tumor growth by combination treatment with drugs against different subpopulations of glioblastoma cells.
    BMC Cancer. 2017;17:905.
    PubMed     Text format     Abstract available


  72. CONDE M, Michen S, Wiedemuth R, Klink B, et al
    Chromosomal instability induced by increased BIRC5/Survivin levels affects tumorigenicity of glioma cells.
    BMC Cancer. 2017;17:889.
    PubMed     Text format     Abstract available


    November 2017
  73. YOMO S, Oguchi K
    Prospective study of 11C-methionine PET for distinguishing between recurrent brain metastases and radiation necrosis: limitations of diagnostic accuracy and long-term results of salvage treatment.
    BMC Cancer. 2017;17:713.
    PubMed     Text format     Abstract available


    October 2017
  74. TRAN LT, Lai HTM, Koriyama C, Uwatoko F, et al
    The association between high birth weight and the risks of childhood CNS tumors and leukemia: an analysis of a US case-control study in an epidemiological database.
    BMC Cancer. 2017;17:687.
    PubMed     Text format     Abstract available


    August 2017
  75. NOH MG, Oh SJ, Ahn EJ, Kim YJ, et al
    Prognostic significance of E-cadherin and N-cadherin expression in Gliomas.
    BMC Cancer. 2017;17:583.
    PubMed     Text format     Abstract available


    July 2017
  76. ZINDLER JD, Bruynzeel AME, Eekers DBP, Hurkmans CW, et al
    Whole brain radiotherapy versus stereotactic radiosurgery for 4-10 brain metastases: a phase III randomised multicentre trial.
    BMC Cancer. 2017;17:500.
    PubMed     Text format     Abstract available


  77. MIELE E, Po A, Begalli F, Antonucci L, et al
    beta-arrestin1-mediated acetylation of Gli1 regulates Hedgehog/Gli signaling and modulates self-renewal of SHH medulloblastoma cancer stem cells.
    BMC Cancer. 2017;17:488.
    PubMed     Text format     Abstract available


    June 2017
  78. WIBROE M, Cappelen J, Castor C, Clausen N, et al
    Cerebellar mutism syndrome in children with brain tumours of the posterior fossa.
    BMC Cancer. 2017;17:439.
    PubMed     Text format     Abstract available


  79. HAYASHI N, Takahashi H, Hasegawa Y, Higuchi F, et al
    A nationwide multi-institutional retrospective study to identify prognostic factors and develop a graded prognostic assessment system for patients with brain metastases from uterine corpus and cervical cancer.
    BMC Cancer. 2017;17:397.
    PubMed     Text format     Abstract available


    May 2017
  80. TEYSSONNEAU D, Daste A, Dousset V, Hoepffner JL, et al
    Metastatic non-muscle invasive bladder cancer with meningeal carcinomatosis: case report of an unexpected response.
    BMC Cancer. 2017;17:323.
    PubMed     Text format     Abstract available


    April 2017
  81. URUP T, Staunstrup LM, Michaelsen SR, Vitting-Seerup K, et al
    Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients.
    BMC Cancer. 2017;17:278.
    PubMed     Text format     Abstract available


  82. TRUBICKA J, Zemojtel T, Hecht J, Falana K, et al
    The germline variants in DNA repair genes in pediatric medulloblastoma: a challenge for current therapeutic strategies.
    BMC Cancer. 2017;17:239.
    PubMed     Text format     Abstract available


  83. LI MX, He H, Ruan ZH, Zhu YX, et al
    Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
    BMC Cancer. 2017;17:245.
    PubMed     Text format     Abstract available


    March 2017
  84. DALAN AB, Gulluoglu S, Tuysuz EC, Kuskucu A, et al
    Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c.
    BMC Cancer. 2017;17:207.
    PubMed     Text format     Abstract available


  85. NARAYAN RS, Fedrigo CA, Brands E, Dik R, et al
    The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures.
    BMC Cancer. 2017;17:204.
    PubMed     Text format     Abstract available


  86. JENSEN SS, Petterson SA, Halle B, Aaberg-Jessen C, et al
    Effects of the lysosomal destabilizing drug siramesine on glioblastoma in vitro and in vivo.
    BMC Cancer. 2017;17:178.
    PubMed     Text format     Abstract available


    February 2017
  87. PANOSYAN EH, Lin HJ, Koster J, Lasky JL 3rd, et al
    In search of druggable targets for GBM amino acid metabolism.
    BMC Cancer. 2017;17:162.
    PubMed     Text format     Abstract available


  88. DEWAN R, Pemov A, Dutra AS, Pak ED, et al
    First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    BMC Cancer. 2017;17:127.
    PubMed     Text format     Abstract available


  89. LI Y, Li J, Woo YM, Shen Z, et al
    Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model.
    BMC Cancer. 2017;17:126.
    PubMed     Text format     Abstract available


  90. SHANNON S, Jia D, Entersz I, Beelen P, et al
    Inhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.
    BMC Cancer. 2017;17:121.
    PubMed     Text format     Abstract available


  91. GERSEY ZC, Rodriguez GA, Barbarite E, Sanchez A, et al
    Curcumin decreases malignant characteristics of glioblastoma stem cells via induction of reactive oxygen species.
    BMC Cancer. 2017;17:99.
    PubMed     Text format     Abstract available


    January 2017
  92. DENG X, Zheng Z, Lin B, Su H, et al
    The efficacy and roles of combining temozolomide with whole brain radiotherapy in protection neurocognitive function and improvement quality of life of non-small-cell lung cancer patients with brain metastases.
    BMC Cancer. 2017;17:42.
    PubMed     Text format     Abstract available


  93. RADES D, Janssen S, Dziggel L, Blanck O, et al
    A matched-pair study comparing whole-brain irradiation alone to radiosurgery or fractionated stereotactic radiotherapy alone in patients irradiated for up to three brain metastases.
    BMC Cancer. 2017;17:30.
    PubMed     Text format     Abstract available


  94. FROMBERG A, Rabe M, Oppermann H, Gaunitz F, et al
    Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cells.
    BMC Cancer. 2017;17:3.
    PubMed     Text format     Abstract available


    December 2016
  95. YOMO S, Hayashi M
    Is upfront stereotactic radiosurgery a rational treatment option for very elderly patients with brain metastases? A retrospective analysis of 106 consecutive patients age 80 years and older.
    BMC Cancer. 2016;16:948.
    PubMed     Text format     Abstract available


    November 2016
  96. WONG ET, Timmons J, Callahan A, O'Loughlin L, et al
    Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas.
    BMC Cancer. 2016;16:914.
    PubMed     Text format     Abstract available


  97. MUROTA Y, Tabu K, Taga T
    Requirement of ABC transporter inhibition and Hoechst 33342 dye deprivation for the assessment of side population-defined C6 glioma stem cell metabolism using fluorescent probes.
    BMC Cancer. 2016;16:847.
    PubMed     Text format     Abstract available


    October 2016
  98. OEHLKE O, Mix M, Graf E, Schimek-Jasch T, et al
    Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    BMC Cancer. 2016;16:769.
    PubMed     Text format     Abstract available


    April 2016
  99. GRAMATZKI D, Roth P, Felsberg J, Hofer S, et al
    Chemotherapy for intracranial ependymoma in adults.
    BMC Cancer. 2016;16:287.
    PubMed     Text format     Abstract available


    January 2016
  100. AKIMOTO J, Fukuhara H, Suda T, Nagai K, et al
    Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain.
    BMC Cancer. 2016;16:36.
    PubMed     Text format     Abstract available


  101. CHOI SA, Kwak PA, Kim SK, Park SH, et al
    In vivo bioluminescence imaging for leptomeningeal dissemination of medulloblastoma in mouse models.
    BMC Cancer. 2016;16:723.
    PubMed     Text format     Abstract available


  102. SCHORB E, Finke J, Ferreri AJ, Ihorst G, et al
    High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix).
    BMC Cancer. 2016;16:282.
    PubMed     Text format     Abstract available


  103. NIIBE Y, Nishimura T, Inoue T, Karasawa K, et al
    Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects.
    BMC Cancer. 2016;16:659.
    PubMed     Text format     Abstract available


  104. FLECKENSTEIN J, Petroff A, Schafers HJ, Wehler T, et al
    Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.
    BMC Cancer. 2016;16:348.
    PubMed     Text format     Abstract available


  105. KIM S, Nam SJ, Kwon D, Kim H, et al
    MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.
    BMC Cancer. 2016;16:363.
    PubMed     Text format     Abstract available


  106. ANGELINO G, De Pasquale MD, De Sio L, Serra A, et al
    NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
    BMC Cancer. 2016;16:512.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Neoplasms of the CNS is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: